A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis

Table 2 Summary of Dose Ratio Between Three-Times Weekly Doses and Once-Daily Doses and Estimated Doses Corresponding to Specific Hemoglobin Response Levels (ITT Population)

Estimated TIW Doses (mg)	95% CI	Selected Hemoglobin Response	Estimated QD Doses (mg)	95% CI	Dose Ratio (TIW/QD)^a	95% CI (Bootstrap)
2.77	0.00–5.82	a change of -0.5 g/dL (minimally effective dose^b)	1.27	0.00–2.63	2.19	0.49–5.20
6.44	3.21–9.99	a change of -0.25 g/dL	3.16	1.58–4.42	2.04	0.95–4.54
10.48	6.98–15.01	a change of 0 g/dL (target dose^c)	5.26	3.91–6.62	1.99	1.25–3.17
14.93	10.71–20.97	a change of 0.25 g/dL	7.58	6.18–9.45	1.97	1.33–2.92
19.85	14.59–27.96	a change of 0.5 g/dL	10.18	8.40–13.08	1.95	1.32–2.89
25.30	18.74–36.16	a change of 0.75 g/dL	13.09	10.68–17.60	1.93	1.27–2.92
31.38	23.27–45.95	a change of 1 g/dL	16.38	13.08–23.33	1.92	1.21–2.98

CI confidence interval, ITT intention-to-treat, QD once daily; TIW, three times weekly
^aBoth the TIW doses and the QD doses were estimated by Bayesian E_max model
^bThe smallest dose that achieves a change of −0.5 g/dL in Hgb over 29 days after being switched from ESA
^cThe dose that achieves a 0 g/dL change in Hgb over 29 days after being switched from rhEPO or its analogs

ISSN: 1471-2369